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Original Article
Prognosis of Gastric Carcinoma Invading 
the Mesocolon
Seong Yeob Ryu, Jae Kyoon Joo, Young Kyu Park, Young Jin Kim, Shin Kon Kim, Jae Hyuk Lee1 and 
Dong Yi Kim, Division of Gastroenterologic Surgery, Departments of Surgery and 1Pathology, 
Chonnam National University Medical School, Gwangju, Korea.
OBJECTIVE: The prognosis is poor when gastric carcinoma invades adjacent organs. We evaluated the
outcome indicators in gastric carcinoma patients with mesocolon invasion.
METHODS: We reviewed the hospital records of 169 gastric carcinoma patients with mesocolon invasion
seen between 1986 and 2000 at Chonnam National University Hospital.
RESULTS: The curative resection rate in gastric carcinoma patients with mesocolon invasion was 29.6%
(50/169). Using Cox’s proportional hazards regression model, curability was the only independent, statistically
significant prognostic parameter (risk ratio, 1.48; 95% confidence interval, 0.90–2.46; p < 0.05). The 5-year
survival rate was higher for patients who underwent curative resection (15.5%) than for those who underwent
non-curative resection (2.6%; p < 0.001). The 5-year survival rate was higher for patients who underwent
resection (7.3%) than for those who did not (bypass and exploration groups, 5.1% and 0%, respectively;
p < 0.001).
CONCLUSION: The results showed improved survival of gastric carcinoma patients with mesocolon
invasion who underwent curative resection compared to those who did not. Improving the prognosis for
patients with mesocolon invasion requires curative resection. [Asian J Surg 2008;31(4):179–84]
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Introduction
Although the incidence of gastric carcinoma is declining
worldwide, it is still one of the leading causes of death
from malignant tumours. Despite improvements in treat-
ment, the overall 5-year survival rate for gastric carcinoma
patients is approximately 30% for those who undergo sur-
gery.1 Furthermore, the prognosis for gastric carcinoma
patients with an invasion of adjacent organs is very poor.2,3
Little is known about the clinicopathological features of
gastric carcinoma patients with mesocolon invasion. In
this retrospective study, we analysed the records of gastric
carcinoma patients with mesocolon invasion to identify
clinicopathological features and outcome indicators. 
We also evaluated the benefit of resection in this group 
of patients.
Patients and methods
A total of 3,342 gastric carcinoma patients underwent gas-
tric resection in the Division of Gastroenterologic Surgery,
Department of Surgery, Chonnam National University
Hospital, Korea, from 1986 to 2000. We only reviewed the
records of 169 patients with mesocolon invasion during
this period. The subjects comprised 127 males (75.1%)
and 42 females (24.9%), with a mean age of 56.8 years.
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For those patients who underwent surgery, diagnosis
was based on histological examination. The effects of the
following on the survival rate were examined: age, gender,
tumour size, tumour location, histological type, presence
of hepatic metastasis and peritoneal dissemination, oper-
ation type and combined resection, lymph node metasta-
sis, extent of lymph node dissection, curability and efficacy
of resection, and intravenous chemotherapy. Histology
was evaluated according to the Japanese Classification of
Gastric Carcinoma.4
Chemotherapy included a variety of drug combina-
tions. The regimens used were 5-fluorouracil (5-FU) plus
cisplatin, FAM (5-FU, doxorubicin, mitomycin C), FAMTX
(5-FU, methotrexate and epirubicin), and FEP (5-FU,
etoposide and cisplatin).
The data were analysed statistically using the χ2 test.
The overall survival rates were calculated using the Kaplan-
Meier method, and the differences between the curves
were tested using the log-rank test. A value of p < 0.05 was
considered statistically significant.
Results
Table 1 summarizes the clinicopathological findings of 169
gastric carcinoma patients who had mesocolon invasion.
The mean tumour size was 7.1 cm, and most of the
gastric carcinomas (55%) were located in the lower third
of the stomach (Table 2). Of the patients with mesocolon
invasion, 21 (12.4%) had no lymph node metastasis (pN0),
whilst this was detected in 148 (87.6%) patients. Dissection
above the D2 lymph node was performed in 72 patients
(42.6%). Combined resection (stomach, colon and meso-
colon) was performed in 58 patients (34.3%). Based on the
grade of anaplasia, 71 (42.0%) tumours were differenti-
ated and 98 (58.0%) were undifferentiated. Hepatic metas-
tases and peritoneal dissemination were found in 12.4%
and 52.7% of the patients with mesocolon invasion,
respectively. In patients with mesocolon invasion, subtotal
gastrectomy was the procedure performed most frequently
(56.2%). The curative resection rate in gastric carcinoma
patients with mesocolon invasion was 29.6% (50/169). Of
the patients with mesocolon invasion, 94 (55.6%) had
intravenous chemotherapy.
In univariate analysis, the factors that influenced 
5-year survival rate were resection and curability (Table 3).
Using Cox’s proportional hazards regression model, only
curability was an independent, statistically significant
prognostic parameter (risk ratio, 1.540; 95% confidence
interval, 0.581–4.079; p < 0.001) (Table 4).
The 5-year survival rates of patients with and without
mesocolon invasion are shown in Figure 1. The 5-year sur-
vival rate was higher in patients without invasion (51.9%)
than in those who had invasion (5.9%; p < 0.001). The 5-
year survival rate was higher in patients with mesocolon
invasion who underwent resection (7.3%) than in those
who did not (bypass and exploration groups, 5.1% and 0%,
respectively; p < 0.001) (Figure 2). The Kaplan-Meier sur-
vival curves of the patients with mesocolon invasion who
underwent curative resection and those who did not are
shown in Figure 3. The 5-year survival rate was higher in
patients who underwent curative resection (15.5%) than
in those who had a non-curative resection (2.6%; p < 0.001).
The 5-year survival rate was also higher in patients who
had mesocolon invasion who underwent dissection above
the D2 lymph node than in those who did not (p < 0.001;
Figure 4).
Discussion
Patients with gastric carcinoma invading adjacent organs
have a poor prognosis.5 In these patients, it is difficult to
Table 1. Clinical features of gastric carcinoma invading the 
mesocolon*
Age, yr 56.8 ± 10.9
Gender
Male 127 (75.1)
Female 42 (24.9)
Combined resection
Yes 58 (34.3)
No 111 (65.7)
Operative type
Total gastrectomy 34 (20.1)
Subtotal gastrectomy 95 (56.2)
Gastrojejunostomy 22 (13.0)
Exploration 18 (10.7)
Curability
Curative 50 (29.6)
Non-curative 119 (70.4)
Intravenous chemotherapy
Yes 93 (55.0)
No 76 (45.0)
*Data presented as mean ± standard deviation or number of
patients (%).
achieve operative curability. Nevertheless, several studies
have reported a survival benefit from tumour resection.6–8
Even though it was non-curative, this benefit was observed
to be better than that following bypass or exploration.
Many gastric carcinoma patients with mesocolon inva-
sion are still classified as incurable at laparotomy. Further-
more, little is known about the survival benefit of resection
in gastric carcinoma patients with mesocolon invasion.
The accumulation of sufficient numbers of patients can
help clarify the clinicopathological characteristics and aid
in better examining the outcome indicators in gastric car-
cinoma patients with mesocolon invasion.
Mesocolon resection is necessary in patients with direct
invasion from distal third gastric carcinomas that infil-
trate the transverse colon or mesocolon. Here, most of the
gastric carcinomas invading the mesocolon (55%) were
located in the lower third of the stomach. Carboni et al9
reported that in advanced gastric carcinoma patients with
infiltration of adjacent organs, the colon/mesocolon is
the second most frequently involved organ in resection.
Our previous study has shown that the most frequent site
of invasion is the colon/mesocolon.10
Kishimoto and Koga have reported that combined
resection of the transverse colon/mesocolon results in 
a poor survival rate in gastric carcinoma patients.11 Adachi
et al12 have also described poor survival rates in gastric
carcinoma patients with mesocolon invasion (3-year 
survival rate, 24%). They thought that the main reason for
the poor surgical outcome was the large number of non-
curative resections. Assessing survival according to the
organs invaded, Kitamura et al13 found that gastric carci-
noma patients who have undergone combined resection
of the colon/mesocolon have a more favourable postop-
erative survival curve than those who have undergone com-
bined resection of the pancreas and liver. Korenaga et al14
have also published encouraging results in the treatment
of gastric carcinoma invading the colon or mesocolon.
The reported postoperative mortality rate for gastric
carcinoma patients who undergo resection ranges from
2.0% to 11.9%.15,16 Carboni et al9 reported that patients
with locally advanced gastric carcinoma that has invaded
adjacent organs may benefit from aggressive surgical
treatment, with acceptable morbidity and mortality.
Martin et al17 demonstrated that gastrectomy with addi-
tional organ resection for gastric carcinoma may be per-
formed with minimal perioperative mortality (4%). Here,
the postoperative mortality from resection in patients
with mesocolon invasion was acceptable. There were four
postoperative deaths (two were > 70 years old) after resec-
tion, which indicates that resection in gastric carcinoma
patients with mesocolon invasion is not associated with
increased postoperative mortality.
Saito et al18 have suggested that resection of the
involved organs, in combination with gastrectomy, should
be performed when lymph node metastasis is not evident.
In contrast, Kobayashi et al19 have reported good survival
in node-positive patients who underwent combined resec-
tion. Adachi et al12 have found that gastric carcinoma that
involves the mesocolon often accompanies peritoneal dis-
semination and extensive lymph node metastasis, and
results in poor survival because of non-curative resection.
To improve the survival rate, they have suggested that
radical surgery with extensive lymph node dissection and
combined organ resection is necessary. We found a survival
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Table 2. Histopathological features of gastric carcinoma invading
the mesocolon*
Tumour size, cm 7.10 ± 3.39
Tumour location
Upper 7 (4.1)
Middle 49 (29.0)
Lower 93 (55.0)
Whole 20 (11.8)
Lymph node metastasis
N (−) 21 (12.4)
N (+) 91 (53.8)
Invasion to other organs
Yes 169 (100)
No 0
Hepatic metastasis
H (−) 148 (87.6)
H (+) 21 (12.4)
Peritoneal dissemination
P (−) 80 (47.3)
P (+) 89 (52.7)
Histological type
Well-differentiated 11 (6.5)
Undifferentiated 98 (58.0)
Extent of lymph node dissection
< D2 97 (57.4)
≥ D2 72 (42.6)
*Data presented as mean ± standard deviation or number of
patients (%).
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benefit with resection in patients with mesocolon inva-
sion, although the resection was intended as non-curative
(5-year survival rate, 4.43%), regardless of lymph node
metastasis.
The impact of postoperative chemotherapy in gastric
carcinoma patients with mesocolon invasion remains
unclear. Some studies have found that postoperative che-
motherapy does not influence the prognosis of patients
Table 3. Univariate analysis of prognostic factors in patients with gastric carcinoma invading the mesocolon
Patients, n Median survival time, mo p
Age, yr 0.9577
< 65 131 7.6
≥ 65 38 10.2
Gender 0.5972
Male 127 8.9
Female 42 7.2
Tumour size, cm 0.6022
< 5 39 8.1
≥ 5 129 8.1
Histological type 0.1875
Differentiated 11 10.1
Undifferentiated 98 8.1
Hepatic metastasis 0.3369
(−) 148 8.6
(+) 21 6.2
Operation 0.0004
Resection 129 10.0
Bypass 22 4.8
Exploration 18 4.1
Curability 0.0021
Curative 50 27.6
Non-curative 119 8.5
Intravenous chemotherapy 0.0589
Yes 76 10.1
No 93 5.1
Table 4. Logistic regression analysis of survival for patients with gastric carcinoma invading the mesocolon
Risk ratio 95% CI p
Gender (male vs. female) 1.335 0.538–3.315 0.533
Age, yr (< 65 vs. ≥ 65) 1.028 0.490–2.158 0.942
Tumour size, mm (< 50 vs. ≥ 50) 0.615 0.281–1.346 0.224
Histological type (differentiated vs. undifferentiated) 2.137 0.639–7.147 0.217
Tumour location (upper vs. lower) 2.375 0.443–12.728 0.313
Resection (yes vs. no) 1.890 0.547–6.527 0.314
Curability (curative vs. non-curative) 1.540 0.581–4.079 < 0.05
Lymph node invasion (yes vs. no) 1.275 0.520–3.128 0.596
Extent of lymph node dissection (< D2 vs. ≥ D2) 0.450 0.164–1.238 0.122
Hepatic metastasis (yes vs. no) 2.283 0.678–7.686 0.183
Intravenous chemotherapy (yes vs. no) 0.738 0.343–1.587 0.437
CI = confidence interval.
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with gastric carcinoma.20,21 Others have reported that
gastric carcinoma patients who receive chemotherapy
have increased survival.22,23 Regarding adjuvant chemo-
therapy, we used postoperative chemotherapy in selected
patients based on their pathological findings, and did not
base this on oesophageal invasion. We did not analyse the
effect of postoperative adjuvant chemotherapy.
In conclusion, we showed that the survival of gastric
carcinoma patients with mesocolon invasion who under-
went curative resection was better than in those who did
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Figure 1. Survival curves of gastric carcinoma patients with and
without mesocolon invasion (with = 5.89%, without = 51.92%; 
p = 0.0001).
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Figure 2. Survival curves of gastric carcinoma patients with
mesocolon invasion according to the operation type (resection =
7.31%, bypass = 5.1%, exploration = 0%; p = 0.0004).
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Figure 3. Survival curves of gastric carcinoma patients with
mesocolon invasion according to curability (curative = 15.45%,
non-curative = 2.64%; p = 0.0003).
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Figure 4. Survival curves of gastric carcinoma patients with
mesocolon invasion according to the extent of lymph node 
dissection (< D2 = 1.84%, ≥ D2 = 11.20%; p = 0.0007).
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not. Improving the prognosis for patients with mesocolon
invasion requires early detection and curative resection.
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